2.58
-0.18 (-6.52%)
| Previous Close | 2.76 |
| Open | 2.76 |
| Volume | 1,331,187 |
| Avg. Volume (3M) | 2,438,603 |
| Market Cap | 231,994,112 |
| Price / Sales | 5.75 |
| Price / Book | 12.61 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -758.05% |
| Diluted EPS (TTM) | -3.04 |
| Quarterly Revenue Growth (YOY) | 310.40% |
| Total Debt/Equity (MRQ) | 49.88% |
| Current Ratio (MRQ) | 3.08 |
| Operating Cash Flow (TTM) | -208.21 M |
| Levered Free Cash Flow (TTM) | -103.52 M |
| Return on Assets (TTM) | -36.80% |
| Return on Equity (TTM) | -140.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Editas Medicine, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.33% |
| % Held by Institutions | 57.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (Baird, 132.56%) | Buy |
| Median | 5.00 (93.80%) | |
| Low | 4.00 (Wells Fargo, 55.04%) | Hold |
| Average | 5.00 (93.80%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 2.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Sep 2025 | 5.00 (93.80%) | Buy | 2.76 |
| 15 Aug 2025 | 5.00 (93.80%) | Buy | 3.03 | |
| Wells Fargo | 03 Sep 2025 | 4.00 (55.04%) | Hold | 2.50 |
| Baird | 13 Aug 2025 | 6.00 (132.56%) | Buy | 3.08 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BURKLY LINDA | - | 2.50 | -710 | -1,775 |
| O'NEILL GILMORE NEIL | - | 2.50 | -5,592 | -13,980 |
| PARISON AMY | - | 2.50 | -458 | -1,145 |
| Aggregate Net Quantity | -6,760 | |||
| Aggregate Net Value ($) | -16,900 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 2.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| O'NEILL GILMORE NEIL | Officer | 03 Sep 2025 | Sell (-) | 5,592 | 2.50 | 13,980 |
| PARISON AMY | Officer | 03 Sep 2025 | Sell (-) | 458 | 2.50 | 1,145 |
| BURKLY LINDA | Officer | 03 Sep 2025 | Sell (-) | 710 | 2.50 | 1,775 |
| Date | Type | Details |
|---|---|---|
| 02 Sep 2025 | Announcement | Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate |
| 28 Aug 2025 | Announcement | Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate |
| 27 Aug 2025 | Announcement | Editas Medicine to Participate in Upcoming Investor Conferences |
| 12 Aug 2025 | Announcement | Editas Medicine Announces Second Quarter 2025 Results and Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |